Top

Cardio-Oncology

Published in:

Open Access 01-12-2021 | Anthracycline | Review

Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer

Authors: Renske Altena, Laila Hubbert, Narsis A. Kiani, Yvonne Wengström, Jonas Bergh, Elham Hedayati

Published in: Cardio-Oncology | Issue 1/2021

Abstract

Background

Cancer treatment-related morbidity relevantly compromises health status in cancer survivors, and efforts to optimise health-related outcomes in this population are vital to maximising healthy survivorship. A pre-treatment assessment – and possibly preventive management strategies – of cancer patients at increased risk for cardiovascular disease (CVD) seems a rational approach in this regard. Definitive evidence for such strategies is largely lacking, thereby impeding the formulation of firm recommendations.

Results

The current scoping review aims to summarise and grade the evidence regarding strategies for prediction and prevention of CVD in adults in relation to oncological treatments. We conducted a scoping literature search for different strategies for primary prevention, such as medical and lifestyle interventions, as well as the use of predictive risk scores. We identified studies with moderate to good strength and up to now limited evidence to recommend primary preventive strategies in unselected patients treated with potentially cardiotoxic oncologic therapies.

Conclusion

Efforts to minimize the CVD burden in cancer survivors are needed to accomplish healthy survivorship. This can be done by means of robust models predictive for CVD events or application of interventions during or after oncological treatments. Up to now there is insufficient evidence to implement preventive strategies in an unselected group of patients treated with potential cardiotoxic oncological treatments. We conclude that randomised controlled trials are needed that evaluate medical and lifestyle interventions in groups at increased risk for complications, in order to be able to influence chronic illness risks, such as cardiovascular complications, for cancer survivors.

Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8(9):784–96. https://doi.org/10.1016/S1470-2045(07)70246-2.CrossRefPubMed

Globocan 2018; https://www.uicc.org/news/new-global-cancer-data-globocan-2018. Date Accessed 2019-09-12.

Fitzmaurice, et al. Global burden of disease cancer collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016. JAMA Oncol. 2018;4(11):1553.CrossRefPubMed

Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–92. https://doi.org/10.1093/annonc/mdl498.CrossRefPubMed

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast Cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast Cancer 2017. Ann Oncol. 2017;28(8):1700–12. https://doi.org/10.1093/annonc/mdx308.CrossRefPubMedPubMedCentral

Shapiro CL. Cancer survivorship. N Engl J Med. 2018;379(25):2438–50. https://doi.org/10.1056/NEJMra1712502.CrossRefPubMed

Mehta LS, Watson KE, Barac A, et al. American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research., cardiovascular disease and breast Cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2017;135:e146–603.

Fogarassy G, Vathy-Fogarassy Á, Kenessey I, Kásler M, Forster T. Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer – a real-world data-based, nationwide classification analysis. Int J Cardiol. 2019;285:47–52. https://doi.org/10.1016/j.ijcard.2019.03.013.CrossRefPubMed

Vincent L, Leedy D, Masri SC, Cheng RK. Cardiovascular disease and Cancer: is there increasing overlap? Curr Oncol Rep. 2019;21(6):47. https://doi.org/10.1007/s11912-019-0796-0.CrossRefPubMed

10.

Colzani E, Liljegren A, Johansson AL, et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol. 2011;29(30):4014–21. https://doi.org/10.1200/JCO.2010.32.6462.CrossRefPubMed

11.

Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity as a risk factor for Anthracyclines and Trastuzumab Cardiotoxicity in breast Cancer: a systematic review and meta-analysis. J Clin Oncol. 2016;34(26):3157–65. https://doi.org/10.1200/JCO.2016.67.4846.CrossRefPubMedPubMedCentral

12.

Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, et al. Association of Cardiovascular Risk Factors with Cardiac Events and Survival Outcomes among Patients with Breast Cancer Enrolled in SWOG clinical trials. J Clin Oncol. 2018;36(26):2710–7. https://doi.org/10.1200/JCO.2017.77.4414.CrossRefPubMedPubMedCentral

13.

Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, et al. Estimating the risks of breast Cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomised trials. J Clin Oncol. 2017;35(15):1641–9. https://doi.org/10.1200/JCO.2016.72.0722.CrossRefPubMedPubMedCentral

14.

Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10(4):391–9. https://doi.org/10.1016/S1470-2045(09)70042-7.CrossRefPubMed

15.

Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472. https://doi.org/10.1161/JAHA.113.000472.CrossRefPubMedPubMedCentral

16.

Rushton M, Johnson C, Dent S. Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population. Curr Oncol. 2017;24(3):176–80. https://doi.org/10.3747/co.24.3349.CrossRefPubMedPubMedCentral

17.

Romond EH, Jeong JH, Rastogu P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomised trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus Trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast Cancer. J Clin Oncol. 2012;31:3792–9.CrossRef

18.

Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–306. https://doi.org/10.1016/j.mayocp.2014.05.013.CrossRefPubMed

19.

Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV, et al. Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. Eur Heart J. 2019;40(48):3913–20. https://doi.org/10.1093/eurheartj/ehz460.CrossRefPubMed

20.

Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat. 2008;107(3):443–50. https://doi.org/10.1007/s10549-007-9803-5.CrossRefPubMed

21.

Lenneman CG, Sawyer DB. Cardio-oncology: an update on Cardiotoxicity of Cancer-related treatment. Circ Res. 2016;118(6):1008–20. https://doi.org/10.1161/CIRCRESAHA.115.303633.CrossRefPubMed

22.

Feldman DR, Ardeshir-Rouhani-Fard S, Monahan P, Platinum Study Group, et al. Predicting cardiovascular disease among testicular Cancer survivors after modern Cisplatin-based chemotherapy: application of the Framingham risk score. Clin Genitourin Cancer. 2018;16(4):e761–9. https://doi.org/10.1016/j.clgc.2018.01.011.CrossRefPubMedPubMedCentral

23.

van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MWJ, Ribot JG, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25(28):4370–8. https://doi.org/10.1200/JCO.2006.10.5296.CrossRefPubMed

24.

Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513–23. https://doi.org/10.1200/JCO.2003.04.173.CrossRefPubMed

25.

Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18(8):1725–32.

26.

Curigliano C, Lenihan H, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90. https://doi.org/10.1016/j.annonc.2019.10.023.CrossRefPubMed

27.

Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893–911. https://doi.org/10.1200/JCO.2016.70.5400.CrossRefPubMed

28.

Elghazawy H, Venkatesulu BP, Verma V, et al. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± trastuzumab: a Meta-analysis of clinical studies. Crit Rev Oncol Hematol. 2020;153:103006.CrossRefPubMed

29.

Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol. 2016;2(8):1030–7. https://doi.org/10.1001/jamaoncol.2016.1726.CrossRefPubMed

30.

Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha VG, et al. A. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncol. 2019;1(1):54–65. https://doi.org/10.1016/j.jaccao.2019.08.006.CrossRefPubMedPubMedCentral

31.

Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104(11):2492–8. https://doi.org/10.1002/cncr.21478.CrossRefPubMed

32.

Dessì M, Piras A, Madeddu C, et al. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. Exp Ther Med. 2011;2(5):1003–9. https://doi.org/10.3892/etm.2011.305.CrossRefPubMedPubMedCentral

33.

Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355–62. https://doi.org/10.1016/j.jacc.2013.02.072.CrossRefPubMed

34.

Georgakopoulos P, Kyriakidis M, Perpinia A, et al. The role of Metoprolol and Enalapril in the prevention of doxorubicin-induced Cardiotoxicity in lymphoma patients. Anticanc Res. 2019;39(10):5703–7. https://doi.org/10.21873/anticanres.13769.CrossRef

35.

Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol. 2014;25(7):1293–311. https://doi.org/10.1093/annonc/mdu012.CrossRefPubMed

36.

Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019;73(22):2859–68. https://doi.org/10.1016/j.jacc.2019.03.495.CrossRefPubMedPubMedCentral

37.

Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–80. https://doi.org/10.1093/eurheartj/ehw022.CrossRefPubMedPubMedCentral

38.

Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017;35(8):870–7. https://doi.org/10.1200/JCO.2016.68.7830.CrossRefPubMed

39.

Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58(9):988–9. https://doi.org/10.1016/j.jacc.2011.05.025.CrossRefPubMed

40.

Macedo AVS, Hajjar LA, Lyon RA, et al. Efficacy of Dexrazoxane in preventing Anthracycline Cardiotoxicity in breast Cancer. JACC CardioOnc. 2019;1(1):68–79.CrossRef

41.

Poklepovic A, Qu Y, Dickinson M, et al. Randomised study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. Cardiooncology. 2018;4:7. https://doi.org/10.1186/s40959-018-0033-2 Epub 2018 Aug 29.CrossRefPubMedPubMedCentral

42.

Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474–81. https://doi.org/10.1161/CIRCULATIONAHA.106.635144.CrossRefPubMed

43.

Kheiri B, Abdalla A, Osman M, Haykal T, Chahine A, Ahmed S, et al. Meta-analysis of Carvedilol for the prevention of Anthracycline-induced Cardiotoxicity. Am J Cardiol. 2018;122(11):1959–64. https://doi.org/10.1016/j.amjcard.2018.08.039.CrossRefPubMed

44.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–7. https://doi.org/10.1182/blood-2007-10-116327.CrossRefPubMedPubMedCentral

45.

Lyman GH, Bohlke K, Khorana AA, American Society of Clinical Oncology, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–6. https://doi.org/10.1200/JCO.2014.59.7351.CrossRefPubMedPubMedCentral

46.

Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102(8):840–5. https://doi.org/10.1161/01.CIR.102.8.840.CrossRefPubMed

47.

Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. JCI. 2001;108(4):585–90. https://doi.org/10.1172/JCI200111334.CrossRefPubMedPubMedCentral

48.

Stump TK, Robinson JK, Yanez B, Penedo F, Ezeofor A, Kircher S, et al. Physicians' perspectives on medication adherence and health promotion among cancer survivors. Cancer. 2019;125(23):4319–28. https://doi.org/10.1002/cncr.32410.CrossRefPubMed

49.

Jones LW, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, et al. Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol. 2014;32(32):3643–50. https://doi.org/10.1200/JCO.2014.56.7511.CrossRefPubMedPubMedCentral

50.

Leger KJ, Baker KS, Cushing-Haugen KL, Flowers MED, Leisenring WM, Martin PJ, et al. Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer. 2018;124(7):1507–15. https://doi.org/10.1002/cncr.31227.CrossRefPubMed

51.

Pelser C, Arem H, Pfeiffer RM, Elena JW, Alfano CM, Hollenbeck AR, et al. Prediagnostic lifestyle factors and survival after colon and rectal cancer diagnosis in the National Institutes of Health (NIH)-AARP diet and health study. Cancer. 2014;120(10):1540–7. https://doi.org/10.1002/cncr.28573.CrossRefPubMed

52.

Okwuosa TM, Ray RM, Palomo A, Foraker RE, Johnson L, Paskett ED, et al. Pre-diagnosis exercise and cardiovascular events in primary breast Cancer: Women’s health initiative. JACC CardioOnc. 2019;1(1):41–50. https://doi.org/10.1016/j.jaccao.2019.08.014.CrossRef

53.

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology breast Cancer survivorship care guideline. J Clin Oncol. 2016;34(6):611–35. https://doi.org/10.1200/JCO.2015.64.3809.CrossRefPubMed

54.

Nayan S, Gupta MK, Strychowsky JE, Sommer DD. Smoking cessation interventions and cessation rates in the oncology population: an updated systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2013;149(2):200–11. https://doi.org/10.1177/0194599813490886.CrossRefPubMed

55.

Cespedes Feliciano EM, Kwan ML, Kushi LH, Weltzien EK, Castillo AL, Caan BJ. Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors. Breast Cancer Res Treat. 2017;162(3):549–57. https://doi.org/10.1007/s10549-017-4133-8.CrossRefPubMedPubMedCentral

56.

Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's healthy eating and living (WHEL) randomised trial. JAMA. 2007;298(3):289–98. https://doi.org/10.1001/jama.298.3.289.CrossRefPubMedPubMedCentral

57.

Kwan ML, Weltzien E, Kushi LH, Castillo A, Slattery ML, Caan BJ. Dietary patterns and breast cancer recurrence and survival among women with early-stage breast cancer. J Clin Oncol. 2009;27(6):919–26. https://doi.org/10.1200/JCO.2008.19.4035.CrossRefPubMed

58.

Jochems SHJ, Van Osch FHM, Bryan RT, et al. Impact of dietary patterns and the main food groups on mortality and recurrence in cancer survivors: a systematic review of current epidemiological literature. BMJ Open. 2018;8(2):e014530. https://doi.org/10.1136/bmjopen-2016-014530.CrossRefPubMedPubMedCentral

59.

Gebruers N, Camberlin M, Theunissen F, Tjalma W, Verbelen H, van Soom T, et al. The effect of training interventions on physical performance, quality of life, and fatigue in patients receiving breast cancer treatment: a systematic review. Support Care Cancer. 2019;27(1):109–22. https://doi.org/10.1007/s00520-018-4490-9.CrossRefPubMed

60.

Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018;1:CD011292.PubMed

61.

Hayward R, Lien CY, Jensen BT, Hydock DS, Schneider CM. Exercise training mitigates anthracycline-induced chronic cardiotoxicity in a juvenile rat model. Pediatr Blood Cancer. 2012;59(1):149–54. https://doi.org/10.1002/pbc.23392.CrossRefPubMed

62.

Howden EJ, Bigaran A, Beaudry R, Fraser S, Selig S, Foulkes S, et al. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. Eur J Prev Cardiol. 2019;26(3):305–15. https://doi.org/10.1177/2047487318811181.CrossRefPubMed

63.

Brown JC, Rickels MR, Troxel AB, Zemel BS, Damjanov N, Ky B, et al. Dose-response effects of exercise on insulin among colon cancer survivors. Endocr Relat Cancer. 2018;25(1):11–9. https://doi.org/10.1530/ERC-17-0377.CrossRefPubMed

64.

Kirkham AA, Lloyd MG, Claydon VE, Gelmon KA, McKenzie DC, Campbell KL. A longitudinal study of the Association of Clinical Indices of cardiovascular autonomic function with breast Cancer treatment and exercise training. Oncologist. 2019;24(2):273–84. https://doi.org/10.1634/theoncologist.2018-0049.CrossRefPubMed

65.

Turner RR, Steed L, Quirk H, et al. Interventions for promoting habitual exercise in people living with and beyond cancer. Cochrane Database Syst Rev. 2018;9:CD010192.PubMed

66.

http://www.fyss.se/wp-content/uploads/2018/01/19.-Cancer.pdf Accessed 17 Jan 2020.

67.

Blaes AH, Shenoy C. Is it time to include cancer in cardiovascular risk prediction tools? Lancet. 2019;394(10203):986–8. https://doi.org/10.1016/S0140-6736(19)31886-0.CrossRefPubMed

68.

Strongman H, Gadd S, Matthews A, Mansfield KE, Stanway S, Lyon AR, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394(10203):1041–54. https://doi.org/10.1016/S0140-6736(19)31674-5.CrossRefPubMedPubMedCentral

Title: Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer
Authors: Renske Altena
Laila Hubbert
Narsis A. Kiani
Yvonne Wengström
Jonas Bergh
Elham Hedayati
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Anthracycline
Breast Cancer
Breast Cancer
Published in: Cardio-Oncology / Issue 1/2021
Electronic ISSN: 2057-3804
DOI: https://doi.org/10.1186/s40959-021-00105-y

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer

Abstract

Background

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

TAVR and cancer: machine learning-augmented propensity score mortality and cost analysis in over 30 million patients

Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: results from the american heart association COVID-19 cardiovascular disease registry

Risk of malignancy long after acute coronary syndrome in selected urban and rural areas and comparison with smoking risk: the ABC-7* study on Heart Disease

Patient reported physical and mental health changes associated with a comprehensive cardiovascular risk reduction program for women with breast cancer receiving potentially cardiotoxic chemotherapy

Echocardiographic myocardial strain analysis describes subclinical cardiac dysfunction after craniospinal irradiation in pediatric and young adult patients with central nervous system tumors

Both intermuscular fat and LVEF decline promote heart failure symptoms in cancer survivors

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page